Seres Therapeutics, Inc.
MCRB Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$1.80
KIRA · Stoqly’s AI analyst, in plain words
- Seres Therapeutics, Inc. had $0.8M of revenue in fiscal 2025. Over five years, revenue changed −52.7% a year on average.
- Its operating margin was −11,910.1%: of every 100 in sales, about −11,910 is left after running the business.
- Seres Therapeutics, Inc. made $5.7M of net profit in fiscal 2025.
- Free cash flow was $0.9M in fiscal 2025, 109.6% of revenue.
Market cap
$17.5M
P/E
—
Revenue
$0.8M
Net income
$5.7M
Free cash flow
$0.9M
Operating margin
−11,910.1%
Seres Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
721.9%
Yes. It keeps 721.9% of every sale as profit.
Does profit turn into cash?
109.6%
Yes. 109.6% of sales ends up as free cash.
How healthy are the accounts?
5 / 7
Mixed. It passes 5 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Seres Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Seres Therapeutics, Inc.
- CIK
- 0001609809
Seres Therapeutics, Inc. · MCRB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $145M | $7.1M | $0.0M | $0.0M | $0.8M |
| Revenue growth | 336.3% | −95.1% | −100.0% | — | — |
| Operating margin | −44.5% | −2,524.0% | — | — | −11,910.1% |
| Net income | −$65.6M | −$250M | −$114M | $0.1M | $5.7M |
| Net margin | −45.2% | −3,509.5% | — | — | 721.9% |
| Diluted EPS | −$0.72 | −$2.31 | −$17.77 | $0.00 | $0.64 |
| Cash | |||||
| Cash from operations | $6.7M | −$229M | −$117M | −$149M | $1.1M |
| Capital expenditure | $9.6M | $9.8M | $8.0M | $0.4M | $0.3M |
| Free cash flow | −$2.9M | −$239M | −$125M | −$149M | $0.9M |
| FCF margin | −2.0% | −3,347.9% | — | — | 109.6% |
| Share count change | 14.9% | 17.9% | −94.1% | 21.4% | 14.2% |
| Debt and strength | |||||
| Cash and short-term investments | $291M | $181M | $128M | $30.8M | $45.8M |
| Debt incl. finance leases | $24.1M | $50.0M | $110M | — | — |
| Shareholders' equity | $132M | $10.8M | −$44.9M | $13.8M | $44.2M |
| Current ratio | 3.7x | 2.3x | 1.8x | 0.9x | 2.6x |
| Interest coverage | −22.2x | −29.9x | −79.1x | — | — |
| Returns and quality | |||||
| Return on equity | −42.8% | −351.6% | — | — | 19.6% |
| Return on tangible equity | −49.9% | −2,319.9% | — | 1.0% | 12.9% |
| Piotroski F-score | 5 | 1 | 2 | 2 | 5 |
| Altman Z'' | −2.2 | −9.5 | −11.3 | −28.6 | −25.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
5 insiders
Of sales under plans
99%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Seres Therapeutics, Inc. · MCRB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.80 a share, the company is worth $17.5M.
Source: SEC EDGAR XBRL filings (CIK 0001609809). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.